Migranil

Quick links to important sections

Migranil

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Migranil

What is Migranil? A Definition and Classification Guide

This section defines the fundamental identity, composition, and general purpose of the medicine Migranil (Pizotifen) in a factual and patient-friendly manner.


Quick Facts: Migranil (Pizotifen)

Property Description
Active ingredient Pizotifen (typically as the malate salt)
Form Tablet (oral administration), Syrup (oral administration)
Pharmacological class Serotonin Antagonist and Antihistamine
Common use Prophylaxis (prevention) of vascular headaches
Origin Synthetic organic compound

What is Migranil, and What is its Active Ingredient?

Migranil is a synthetic prescription medicine whose active ingredient is Pizotifen, which is generally administered for oral administration as a tablet or syrup. Pizotifen is a synthetic organic compound, a derivative of benzocycloheptathiophene, typically formulated as the salt Pizotifen malate or Pizotifen hydrogen malate. This medicine is a single-ingredient product, with its entire therapeutic effect derived from Pizotifen. Its availability in both tablet and syrup forms is a distinguishing factor, offering flexibility for patient groups who may have difficulty swallowing tablets.

Pizotifen acts as an antagonist at 5-HT (serotonin) receptors and H1 (histamine) receptors, demonstrating a dual blocking action on key neurochemicals involved in headache development. The compound is intended to reduce the impact of these signaling substances.


What Type of Medicine is Pizotifen?

Pizotifen is classified in the high-level pharmacological class as a Serotonin and Tryptamine Antagonist, which includes its secondary properties as an antihistamine. Its core function is the potent blockade of specific 5-HT2A and 5-HT2C serotonin receptors. This mechanism supports the role of Pizotifen in headache prevention. The therapeutic relevance of Pizotifen's unique polyvalent receptor affinity is recognized for stabilizing the neurovascular system. The overall purpose of Migranil is to provide prophylactic treatment—it is used to prevent the development of vascular headaches over time.

Regulatory References

  1. Pizotifen - DrugBank Online

What side effects are possible with Migranil?

Possible side effects and safety information

Official regulatory documents classify the possible adverse reactions of Migranil (Pizotifen) based on their frequency and the system-organ class (SOC) affected. The most frequently observed effects involve metabolism and the central nervous system, typically appearing at the beginning of treatment.

Frequency-Classified Adverse Reactions

The adverse reactions are grouped into standard frequency categories, based on government-approved labeling:

Frequency Category Examples of Documented Effects (SOC)
Very Common (>1/10) Increased appetite, Weight increased (Metabolism and nutrition disorders)
Common (1/100 to <1/10) Sedation (somnolence), Dizziness (Nervous system disorders), Fatigue, Dry mouth
Rare to Very Rare Hypersensitivity reactions, Seizures, Depression, Hallucination, Urticaria
Frequency Not Known Jaundice, Hepatitis (Hepatobiliary disorders)

Safety Considerations and Special Populations

Official labeling contains specific notes concerning patient safety. Caution is required when using the medicine in individuals with pre-existing conditions such as narrow-angle glaucoma or urinary retention. Furthermore, the central effects of other Central Nervous System depressants, including alcohol, may be enhanced.

Regarding specific patient populations, caution is advised for older adults due to the potential for increased dysfunction in organs like the liver or kidneys. Regulatory information also specifies that the use of Migranil in children under 12 years is generally contraindicated. Finally, a safety pattern noted in regulatory documentation is the occurrence of acute withdrawal symptoms (e.g., anxiety, tremor, sleep disorder) following abrupt cessation.

Overdose and Emergency Response

Overdose and When to Seek Help for Migranil

The combination of ergotamine and caffeine, the active components of Migranil, presents a specific overdose risk, requiring immediate medical attention if suspected. Overdose can lead to a state of ergotism, which is characterized by intense and prolonged vasoconstriction (narrowing of blood vessels) that may lead to tissue ischemia.

Documented Overdose Symptoms

Symptoms of an overdose primarily affect the cardiovascular, nervous, and gastrointestinal systems, and may include:

System Affected Manifestations
Cardiovascular/Vascular Pale, cold, or blue coloration of the fingers and toes; numbness, tingling, or pain in the extremities; weak or absent pulses; changes in heart rate (slow or fast); chest pain; changes in blood pressure.
Neurological/Systemic Headache, blurred vision, dizziness, confusion, decreased awareness, seizures, severe sleepiness, or loss of consciousness.
Gastrointestinal Severe or continuing nausea, vomiting, or diarrhea; severe stomach pain; or intense thirst.

Required Emergency Action

Immediate medical help must be sought at once if you suspect an overdose or experience any of these serious symptoms. It is vital to call emergency services or a poison control center right away. Do not wait for symptoms to worsen.

Critical Overdose Risk

A critical, life-threatening risk called acute ergot toxicity (or ergotism) may occur if Migranil is taken in combination with potent inhibitors of the CYP 3A4 liver enzyme, which include certain antibiotics (e.g., erythromycin, clarithromycin) and HIV protease inhibitors. This combination dramatically increases the drug's levels in the body, raising the risk of severe blood vessel constriction and potential ischemia of the brain or extremities.

Therapeutic Uses of Migranil

What Migranil Treats: Main Uses and Benefits

Migranil (Pizotifen) may be part of symptomatic management for conditions characterized by periods of heightened symptoms related to physical discomfort, generally focusing on reducing the overall symptom load over time. The medicine is generally used for the prophylactic management of recurrent vascular headaches.


Primary Therapeutic Focus

This medication is applied in clinical settings for the prevention of recurrent or episodic manifestations, including classical migraine, common migraine, and the management of cluster headache (periodic migrainous neuralgia). It is relevant when symptoms that interfere with daily functioning create noticeable physiological strain. The primary therapeutic focus supports the patient during difficult episodes by easing the overall symptom load, as it is relevant for managing symptoms that interfere with daily comfort.

It is considered relevant in contexts involving heightened systemic burden, offering symptomatic relief that helps patients cope more steadily.

The application is relevant in areas where additional symptomatic support is needed, contributing to improved comfort during symptomatic periods. It is considered relevant in contexts involving heightened systemic burden where functional stability becomes affected; it may assist with maintaining functional stability and supports patients during episodes of heightened discomfort.


Quick Fact: Relief for Recurring Headaches

Feature Benefit
Symptom Management Supports the management of symptoms that interfere with daily comfort.
Clinical Context Relevant for long-term preventive care.
Patient Benefit Assists with maintaining functional stability.

Eligibility and Restrictions for Use

Migranil, a combination of ergotamine tartrate and caffeine, is indicated for the acute treatment of migraine headaches with or without aura, and certain other vascular headaches. It is not intended for the chronic daily prevention of migraines or for the management of non-migraine headaches.

Who Can Use Migranil?

  • Adults diagnosed with acute migraine or cluster headaches who have not responded adequately to simpler analgesics.
  • The medication works best when taken at the first sign of a migraine attack.

Who Cannot Use Migranil? (Contraindications)

Migranil is contraindicated in patients with conditions that predispose them to harmful vasoconstriction (narrowing of blood vessels) or specific drug interactions. It should not be used by individuals with:

  • Cardiovascular Disease: Including peripheral vascular disease, coronary artery disease (such as angina or history of myocardial infarction), or poorly controlled hypertension (high blood pressure).
  • Hepatic or Renal Impairment: Severe liver or kidney disease.
  • Infections: Sepsis (severe blood infection).
  • Pregnancy and Lactation: It is contraindicated in women who are or may become pregnant due to the risk of fetal harm, and in nursing mothers as it can pass into breast milk.
  • Hypersensitivity: Known allergy to ergotamine, caffeine, or any other component of the formulation.
  • Drug Interactions: Concomitant use with potent CYP 3A4 inhibitors (e.g., certain macrolide antibiotics like erythromycin, or HIV protease inhibitors) is strictly contraindicated due to the risk of acute ergot toxicity (ergotism), which can lead to severe and life-threatening vasospasm.

What should I know about interactions with other medicines?

Migranil, which often contains ergotamine or dihydroergotamine, and sometimes caffeine and other compounds, has several significant drug and substance interactions that require careful consideration by a healthcare professional.

Major Drug Interactions (Contraindicated)

The co-administration of Migranil with strong inhibitors of the CYP3A4 enzyme is generally contraindicated due to the potential for life-threatening vasospasm (severe narrowing of blood vessels), which can lead to cerebral ischemia or ischemia of the extremities. Examples of such inhibitors include:

  • Macrolide Antibiotics: Erythromycin, Clarithromycin, Troleandomycin
  • Antifungal Agents: Ketoconazole, Itraconazole
  • HIV Protease Inhibitors: Ritonavir, Nelfinavir, Indinavir

Additionally, Migranil should not be taken within 24 hours of other vasoconstrictive migraine medications, specifically triptans (e.g., Sumatriptan, Rizatriptan), as the combined effect can lead to dangerously elevated blood pressure and prolonged vasospasm.

Other Significant Interactions

Drug/Substance Category Potential Interaction Effect
Vasoconstrictors (e.g., Nicotine) May enhance the vasoconstricting effects, increasing the risk of ischemia.
Beta-Blockers (e.g., Propranolol) May potentiate the vasoconstrictive action of ergot alkaloids.
Grapefruit Juice May increase the plasma concentration of the active ingredients, increasing the risk of adverse effects.

Patients should inform their doctor of all current medications and supplements, including over-the-counter products, to manage the risk of these interactions.

Mechanism of Action

How Migranil Works


Molecular Blockade of Serotonin and Histamine

The core mechanism of Pizotifen involves a polyvalent antagonism that targets both 5-HT2 serotonin receptors and histamine H1 receptors. By blocking these primary sites, the compound limits the binding and subsequent activation of associated signaling pathways by vasoactive neurochemicals—serotonin and histamine. This molecular blockade alters the initial signaling steps within the biochemical cascade.


Modulation of Neurovascular Tone and Permeability

The combined receptor antagonism results in the modulation of neurovascular tone. The mechanism attenuates the hyper-reactivity of cranial blood vessels and limits the histamine-driven increase in vessel permeability. This action restricts the extravasation of fluid and pro-nociceptive mediators, which contributes to the modulation of nociceptive signaling and affects the physiological pain threshold.


⏳ Mechanism Constraints: Sustained Pathway Modulation

The mechanism relies on continuous receptor saturation for its sustained pathway modulation. Consequently, the mechanism is not suited for rapid interruption of established signal cascades. This sustained modulation adjusts the baseline neurochemical signaling, but the mechanism is mechanistically insufficient to halt the rapid, established cascade of an acute neurovascular episode.

Dosage and Administration Information

How Migranil is Used: Administration Principles

Migranil (Pizotifen) is a medicine intended for long-term prophylactic use in preventing recurrent vascular headaches. The administration route is exclusively oral, utilizing either a tablet or syrup formulation.

Dosing and Frequency

The general principle of use involves starting with a low dose and gradually increasing (titrating) it to establish the appropriate maintenance dose. The starting dose for adults is typically 0.5 mg daily. This initial dose is often administered as a single dose at bedtime to align with treatment tolerance.

Dosing Range Instruction
Average Daily Maintenance 1.5 mg
Maximum Daily Limit 4.5 mg

Administration of the maintenance dose can be either as a single dose taken at night or divided into three separate administrations throughout the day. To adequately assess the effectiveness of the preventive treatment, clinical application involves a minimum continuous trial period of two to three months.

Administration Contexts

The medicine offers flexibility in intake; it can be taken with or without food. For the tablet form, the medicine should be swallowed whole. Regarding population-specific guidelines, the total daily dose for children over two years old is generally limited to a maximum of 1.5 mg, with a single dose cap of 1 mg at night. Caution and potential dosage adjustment are required for patients with hepatic or renal impairment due to the drug’s metabolism and excretion profile.

Recent Clinical Evidence

Migranil: Overview of Research Evidence

Overview of Studies for Recurrent Vascular Headaches

Migranil (Pizotifen) was evaluated in research exploring conditions characterized by fluctuating or episodic manifestations, specifically for research exploring prophylaxis of recurrent vascular headaches such as migraine. Clinical research examined measurements related to physical discomfort and overall symptom patterns over time. The existing evidence includes a collection of historical randomized controlled trials (RCTs). More recent systematic reviews and meta-analyses were applied in studies examining patient-reported experiences by assessing the consistency of those initial trial findings.

How Migranil Was Compared to Placebo and Other Medications

Trials were evaluated in comparison to an inactive placebo to monitor observed patterns in outcomes describing episodic or acute changes. Some trials reported measurements concerning the proportion of individuals whose frequency of migraine attacks changed during the study period. However, recent systematic reviews have classified the findings concerning clinical change measurements in relation to placebo as being based on evidence of very low certainty. Research also explored comparative patterns when Migranil was evaluated alongside other established preventive medications; data show patterns related to measured outcomes not being distinct from several of these other comparative medications. The overall quality of this comparative evidence varies across studies.

Evidence in Special Populations and Limitations

Research was studied for use in children and young people (under 18 years). However, the findings were mixed, and data for certain groups remain insufficient. The core outcome research primarily involved short-term intervention periods, and long-term effects are not fully established through high-quality controlled trials. Major scientific bodies note that the foundational RCTs were conducted decades ago. Consequently, evidence quality varies across studies, and the certainty remains low for some core questions.

Frequently Asked Questions (FAQ)

Common questions about Migranil (FAQ)

Q: How quickly can I expect Migranil to start working after taking it?

Regulatory documents indicate that the acute treatment formulation's active component reaches its highest level in the blood about 2 hours after ingestion. This indicates when the highest concentration of the active ingredient is generally reached in the bloodstream. However, the patient's experience of onset can vary widely.

Q: How long does the effect of one dose of Migranil usually last?

Official pharmacokinetics data describes how the ingredients are processed by the body. The elimination half-life for the acute treatment's main active ingredient is approximately 2 hours, meaning its concentration drops by half in that time. The effects of a single dose may vary, and recurrence of symptoms may be noted as the medication level decreases.

Q: Is Migranil known to cause headaches if taken too often?

Yes, official warnings state that the frequent use of ergotamine-containing products can lead to a condition called Medication Overuse Headache (MOH), also known as rebound headaches. Regulatory labeling emphasizes strict adherence to prescribed limitations to mitigate this risk. This is a known risk where regular consumption of acute pain relievers causes headaches to occur more often or become chronic.

Q: Is the sensation of tingling or tightness after taking Migranil a common side effect?

Official documentation lists tingling, numbness, chest pain, and chest tightness as documented adverse reactions. Because these sensations, particularly chest or throat tightness, may be signs of a serious complication like severe blood vessel narrowing (vasospasm), official safety information states that these symptoms must be promptly discussed with a healthcare professional.

Q: Is it typical for a prescription of Migranil to be limited to a certain number of doses per month?

Official guidelines and regulatory labeling set strict limits on the frequency of use to reduce the risk of serious side effects and Medication Overuse Headache. For instance, the maximum is typically limited to no more than 10 tablets or 5 suppositories within a 7-day period. The limits established in the regulatory documentation are a critical component of safety instructions.

Q: What does it mean if Migranil does not fully relieve my symptoms after two hours?

Acute treatment guidelines specify a maximum number of doses that may be taken for a single headache episode. If the medication has not provided sufficient relief after the maximum limit has been reached, the official guidance emphasizes that a consultation with a healthcare professional may be needed.

Q: Can Migranil be taken if a migraine attack includes nausea or vomiting?

Migraine attacks often involve nausea and vomiting. Official product information notes that some forms of the medication, such as rectal suppositories, may be a consideration for individuals experiencing severe vomiting to ensure the drug is properly absorbed.

Q: Does Migranil interact with common medications used for anxiety or depression?

Regulatory documents include warnings about potential interactions between Migranil and certain medications used for mental health conditions. Specifically, interactions may occur with drugs that affect the same liver enzymes (CYP3A4). Patients are generally advised to ensure their full medication list is reviewed by a healthcare professional, including treatments for anxiety or depression.

Q: Why do some people experience a return of symptoms after Migranil wears off?

The return of headache symptoms after the medication wears off is a pattern known as recurrence, which may be related to the plasma half-life of the active ingredients. This pattern can also be a signal associated with the development of Medication Overuse Headache (MOH).

Q: Do any official warnings exist about operating machinery or driving after taking Migranil?

Yes, official warnings exist about operating machinery or driving. Side effects such as drowsiness, dizziness, and sedation are documented, and these may impair a person's ability to concentrate and react. The warnings recommend that individuals should ascertain their response to the medication before engaging in activities requiring full mental alertness.

Q: Can I take Migranil if I am currently taking a preventative migraine medication?

Regulatory sources strictly contraindicate the use of the acute version of Migranil with other vasoconstrictive acute migraine medications, such as triptans. This is due to a high risk of dangerously elevated blood pressure and prolonged blood vessel narrowing. Reviewing all medications with a healthcare professional is necessary to manage the use of Migranil alongside preventative treatments.

Q: What kind of medical monitoring might be required when starting Migranil?

Official information indicates that medical monitoring may be required, particularly when starting treatment or when dose adjustments are made. This monitoring assesses the risk of serious side effects, including signs of cardiovascular complications and potential toxicity in patients with liver or kidney impairment.

Q: Is there any research evidence on Migranil use in patients with a history of stroke?

The acute formulation is strictly contraindicated in patients with conditions that predispose them to harmful blood vessel narrowing (vasoconstriction). This includes patients with a history of stroke. The risk associated with vasoconstriction is a documented warning for ergotamine use.

Q: Is Migranil considered a first-line or second-line treatment option for migraine?

Based on official clinical treatment guidelines, ergotamine-containing products are frequently classified as a second-line or reserve option for acute migraine treatment. They are typically reserved for individuals who have not experienced adequate relief from first-line therapies.

Q: What are the descriptive features of the 'Medication Overuse Headache' warning associated with Migranil?

Medication Overuse Headache (MOH) associated with Migranil is described as a pattern of chronic headaches that occur frequently, often daily or nearly daily. These headaches result directly from the regular, excessive use of acute migraine treatments like ergotamine.

Q: What kind of evidence is there on Migranil's impact on migraine aura?

The acute treatment combination is officially indicated for the management of migraine headaches that occur both with or without aura. Aura refers to the sensory disturbances that some people experience before the onset of the migraine head pain.

Q: How is the safety of Migranil categorized by regulatory bodies?

Regulatory bodies categorize the safety of Migranil based on documented risks. For example, the acute ergotamine/caffeine combination is strictly contraindicated in pregnancy due to the risk of fetal harm and is classified as Pregnancy Category X. Other safety categorization is based on the frequency of side effects and contraindications.

Q: Why do some users report a chest or throat pressure feeling when using Migranil?

Chest or throat pressure is a documented adverse reaction linked to the vasoconstrictive mechanism of ergotamine, which causes blood vessels to narrow. Official safety instructions emphasize that this is a serious symptom that warrants prompt consultation with a healthcare professional.

Q: Is Migranil used for every kind of headache, or just migraine?

Migranil is indicated for the prevention of vascular headaches (prophylactic version) or the acute treatment of migraine and certain other vascular headaches (acute version). It is not intended for the management of non-vascular headaches, such as tension-type headaches, as noted in the medication's official indications.

Q: What is meant by the official term 'contraindication' for Migranil?

The term 'contraindication' refers to any specific situation or condition in which a medication should not be used. Regulatory documents list contraindications because using the medicine under these circumstances may be harmful or pose a serious risk to the person.

Q: What is the average time window after a dose when I can take other types of pain medication?

Official safety warnings emphasize that other vasoconstrictive migraine medications, like triptans, must not be taken within 24 hours of the acute Migranil dose. However, a specific official time window for taking non-vasoconstrictive pain relievers after a dose is generally not provided in regulatory documents.

Q: Can Migranil be taken with a common cup of coffee or caffeine products?

The acute version of Migranil is formulated with caffeine, which is noted for its intended effect. While the prophylactic version does not contain caffeine, regulatory cautions indicate that managing total caffeine intake from all sources is important, as it can potentially complicate treatment or enhance central nervous system effects.

How should Migranil be stored and disposed of?

How to Store and Dispose of Migranil (Pizotifen)

Official regulatory documents define strict conditions for storing and disposing of Migranil tablets to maintain stability and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store at room temperature, not exceeding 25 C.
Protection Must be protected from light and moisture.
Packaging Store only in the original package.
Child Safety Keep out of the sight and reach of children (Mandatory).

Disposal Instructions

Expired or unused Migranil must be discarded according to local disposal regulations. It is advised not to dispose of this medicine by pouring it into wastewater unless specifically instructed by a healthcare provider or official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Migranil found in:

A-Z Index: